# Evaluating Newly Approved Drugs for Multidrug-resistant TB

> **NCT02754765** · PHASE3 · COMPLETED · sponsor: **Médecins Sans Frontières, France** · enrollment: 754 (actual)

## Conditions studied

- Tuberculosis, Multidrug-Resistant
- Infection, Bacterial
- Pulmonary Tuberculoses

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** Delamanid
- **DRUG:** Clofazimine
- **DRUG:** Levofloxacin
- **DRUG:** Moxifloxacin
- **DRUG:** Linezolid
- **DRUG:** Pyrazinamide
- **DRUG:** Control arm MDR-TB regimen, consistent with WHO guidelines

## Key facts

- **NCT ID:** NCT02754765
- **Lead sponsor:** Médecins Sans Frontières, France
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 754 (ACTUAL)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754765, "Evaluating Newly Approved Drugs for Multidrug-resistant TB". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02754765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*